Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HUMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq deficiency notice for failing to maintain minimum $1.00 bid price requirement for 30 consecutive days.
Humacyte receives Nasdaq delisting warning for stock price below $1.00
Filed May 8, 2026 · Period ending May 4, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Humacyte on May 4 that its stock closed below the required $1.00 minimum bid price for 30 consecutive business days, violating listing rules.
Item 3.01 verify on EDGAR → -
high
Company has until November 2, 2026 (180 days) to regain compliance by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days.
Item 3.01 verify on EDGAR → -
high
Management acknowledged no assurance exists that the company will successfully regain compliance within the deadline, though it will monitor the stock price and consider available options.
Item 3.01 verify on EDGAR → -
medium
The stock continues trading on Nasdaq Global Select Market under ticker HUMA during the compliance period, with no immediate impact on business operations or SEC reporting.
Item 3.01 verify on EDGAR →
Summary
Humacyte disclosed receiving a deficiency notice from Nasdaq on May 4, 2026, warning that its common stock has traded below the exchange's required $1.00 minimum bid price for 30 consecutive business days. This triggers a formal compliance process that gives the company 180 days—until November 2, 2026—to cure the violation by achieving a closing bid price of at least $1.00 for 10 consecutive trading days.
While the stock remains listed and trading normally under ticker HUMA for now, failure to regain compliance could ultimately lead to delisting from the Nasdaq Global Select Market. For retail investors, this is a significant warning sign about the company's market valuation and investor confidence. A stock price persistently below $1.00 often reflects fundamental business challenges or market skepticism.
Management has not outlined specific remedial actions beyond monitoring the situation, and explicitly stated there's no guarantee of success. Investors should watch whether the company announces concrete steps such as a reverse stock split, business developments that could boost the share price, or any updates on the compliance timeline as the November deadline approaches.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a) (1).
Humacyte disclosed receiving a deficiency letter from Nasdaq on May 4, 2026, notifying the company that its common stock bid price closed below the required $1.00 minimum for 30 consecutive business days ending May 1, 2026. This violates Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market.
Added in current filing · verify on EDGAR →
In accordance with Nasdaq Listing Rule 5810(c) (3) (A), the Company has been provided an initial period of 180 calendar days, or until November 2, 2026, to regain compliance. To regain compliance, the closing bid price of the Common Stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before November 2, 2026.
The company has been granted a 180-day compliance period ending November 2, 2026. To cure the deficiency, the stock's closing bid price must reach or exceed $1.00 per share for at least 10 consecutive business days before the deadline. If achieved, Nasdaq will close the matter with written confirmation.
Added in current filing · verify on EDGAR →
The Company intends to monitor the bid price of the Common Stock and will consider options available to it to achieve compliance. There can be no assurance that the Company will regain compliance during this period.
Management stated it will monitor the stock price and evaluate available options to regain compliance, but explicitly cautioned that there is no guarantee the company will successfully meet the bid price requirement within the 180-day window.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify